Making thrombolysis safer in stroke
- PMID: 28428237
- DOI: 10.1182/blood-2017-02-765610
Making thrombolysis safer in stroke
Conflict of interest statement
Conflict-of-interest disclosure: D.G. has received consultant fees from several pharmaceutical companies (Aronora, Bayer, Dyax, Ionis, Merck, Novartis, Ono) with an interest in inhibition of contact activation proteases for therapeutic purposes.
Comment on
-
Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke.Blood. 2017 Apr 20;129(16):2280-2290. doi: 10.1182/blood-2016-09-740670. Epub 2017 Jan 27. Blood. 2017. PMID: 28130211 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical

